Article
Gastroenterology & Hepatology
Jing Yu, Zhan Wang, Hua Zhang, Yi Wang, Dong-Qing Li
Summary: Survivin-positive CTCs may serve as a promising predictor of tumor progression and metastasis in HCC patients, with significantly higher counts correlating with tumor stage and degree of differentiation. Survivin overexpression can induce cell proliferation and invasion in HCC cells.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Oncology
Jing-Jing Yu, Ya-Ni Li, Chang Shu, Hui-Yuan Yang, Zhao Huang, Ran Tao, Yue-Yue Chen, Xiao-Ping Chen, Wei Xiao
Summary: A retrospective analysis found that HCC patients with portal vein tumor thrombosis (PVTT) had significantly higher preoperative circulating tumor cell (CTC) counts compared to those without PVTT. Patients with CTC counts ≥ 2 had significantly lower overall survival and disease-free survival rates. Therefore, preoperative CTC counts have the potential to be a valuable clinical tool in predicting the prognosis of HCC patients with PVTT.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Tian-Run Lv, Hai-Jie Hu, Parbatraj Regmi, Fei Liu, Fu-Yu Li
Summary: Sarcomatoid hepatocellular carcinoma (SHCC) is a rare subtype of primary liver malignancies. Compared to conventional hepatocellular carcinoma (HCC), SHCC has worse prognosis and exhibits more aggressive behavior.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Xihua Yang, Hanghang Ni, Zhan Lu, Jie Zhang, Qian Zhang, Shangwu Ning, Lunan Qi, Bangde Xiang
Summary: This study aimed to explore the relationship between mesenchymal circulating tumor cells (M-CTCs) and Ki67 in hepatocellular carcinoma (HCC) and their ability to predict prognosis. The results showed that the presence of M-CTC correlated with high Ki67 expression in HCC patients, and both factors were associated with poor prognosis. Furthermore, the combination of M-CTC and Ki67 was a useful prognostic indicator for predicting overall survival in HCC patients.
Article
Oncology
Lina Zhao, Zhifa Zheng, Yunhe Liu, Fei Liu, Xiaoxin Li, Zhihong Wu
Summary: This study identifies a correlation between circulating tumor cells (CTCs) and recurrence risk in hepatocellular carcinoma (HCC) patients, demonstrating the potential of CTCs as an effective prognostic tool.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Zuxi Li, Meijuan Song, Shangjun Han, Chuanwei Jin, Jing Yang
Summary: Circulating tumor cells (CTC) are associated with the prognosis of patients with gastric cancer. Gastric cancer patients with positive CTC may have a poorer prognosis compared to those with CTC-negative tumors. CTC-positive patients have more advanced TNM staging, poorer tumor differentiation, and earlier distant metastasis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Qian Zhang, Wanting Xing, Jie Zhang, Junwen Hu, Lunan Qi, Bangde Xiang
Summary: This study revealed that CK19 positivity was common in HCC patients and associated with lower tumor-free survival rates. Additionally, high CTC count and high percentage of mesenchymal CTCs were closely related to CK19 expression.
ONCOTARGETS AND THERAPY
(2021)
Article
Medicine, General & Internal
Jun Deng, Wei Chen, Xiaoxia Wu, Yan Zhou, Jun Li
Summary: The number of circulating tumor cells (CTCs) can effectively predict the survival time of patients with advanced hepatocellular carcinoma (HCC), and a prediction model combining CTCs and tumor number can more accurately predict patient prognosis.
Review
Immunology
Jun-Shuai Xue, Zi-Niu Ding, Guang-Xiao Meng, Lun-Jie Yan, Hui Liu, Hai-Chao Li, Sheng-Yu Yao, Bao-Wen Tian, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Dong-Xu Wang, Tao Li
Summary: NK cells and their inhibitory receptors have prognostic value for HCC, with high levels of NK cells associated with better overall survival and disease-free survival. The prognostic role of NK cell activating receptors remains unclear.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Yinggang Hua, Jingqing Dong, Jinsong Hong, Bailin Wang, Yong Yan, Zhiming Li
Summary: Hepatocellular carcinoma is a highly malignant tumor with a poor prognosis. Circulating tumor cells, shed from the tumor, play a crucial role in the early diagnosis and monitoring of HCC patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Maria Lola Espejo-Cruz, Sandra Gonzalez-Rubio, Javier Zamora-Olaya, Victor Amado-Torres, Rafael Alejandre, Marina Sanchez-Frias, Ruben Ciria, Manuel De la Mata, Manuel Rodriguez-Peralvarez, Gustavo Ferrin
Summary: Liquid biopsy with circulating tumor cells (CTCs) has emerged as a useful tool for diagnosing and monitoring therapeutic responses in hepatocellular carcinoma (HCC). Although CTCs may aid decision-making processes, there are still uncertainties and technical caveats to be resolved before this methodology has a true impact on clinical practice guidelines.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Qiao Zhang, Feng Xia, Ali Mo, Weiming He, Jiazhen Chen, Weiqiao Zhang, Weiqiang Chen
Summary: Preoperative testing of circulating tumor cells (CTCs) can reliably indicate whether HCC patients will benefit from preoperative TACE. In CTC-positive patients, preoperative TACE can reduce early recurrence and improve long-term survival outcomes. However, the overall HCC patient population and CTC-negative patients do not benefit from preoperative TACE.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Chengying Huang, Xiaoli Lin, Jinmei He, Nan Liu
Summary: The presence of CTCs in peripheral blood is associated with poor survival outcomes for patients, especially in the pre-therapy, surgery, and RT-PCR subgroups. Patients detected with CTCs using physical or immunological methods also show significantly worse OS compared to other enrichment methods.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Immunology
Lin Ding, Qian Yu, Shuo Yang, Wen-Jing Yang, Te Liu, Jing-Rong Xian, Tong-Tong Tian, Tong Li, Wei Chen, Bei-Li Wang, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang, Wei Guo
Summary: This study suggests that HHLA2 is an independent prognostic biomarker for HCC patients, and it can activate the cell cycle and foster an immunosuppressive tumor microenvironment by enriching exhausted CD8+ T cells. Additionally, low expression of HHLA2 may be associated with promoter hypermethylation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Genlin Lu, Jian Lin, Guoqiang Song, Min Chen
Summary: The meta-analysis showed that CTNNB1 mutation in HCC is associated with favorable clinicopathological features and survival rates. CTNNB1 mutation is significantly linked to differentiation, TMN stages, liver cirrhosis, and HBV infection, but not with tumor size, metastasis, vascular invasion, and HCV infection.